Define and measure the real-world impact of drugβdisease programs, combining public health and epidemiological analysis with stakeholder engagement and clear communication to help move promising treatments toward patients.
Evaluates and advances promising drug-repurposing opportunities by synthesizing scientific evidence, identifying research gaps, and coordinating laboratory, real-world evidence, clinical, and external-partner studies.